Advertisement

Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study

  • B. García-Chías
  • E. FigueroEmail author
  • B. Castelo-Fernández
  • J. L. Cebrián-Carretero
  • R. Cerero-Lapiedra
Original Article
  • 41 Downloads

Abstract

Purpose

To determine the prevalence of professionally reported oral side effects of chemotherapy and the self-reported oral side effects and whether both prevalences could be related to the periodontal risk of the patients.

Methods

A cross-sectional study with patients undergoing chemotherapy treatment was carried out. Demographic, oral hygiene habits, and cancer-related data were collected while the patient was receiving the chemotherapy infusion. Patient’s oral status, measured according to the oral-assessment guide for patients in hospital environments, patient-related outcomes (PROMs), measured by a visual analogue scale, and patient’s periodontal risk were analyzed using validated questionnaires. Data was reported in means and standard deviations (SD) in quantitative variables and in counts, prevalence, and 95% confidence intervals (CI) in qualitative variables. ANOVA test and chi-squared tests were used to compare oral side effects among different periodontal risk groups.

Results

Three hundred sixty-nine patients were included in the study. The prevalence of professionally reported oral side effects was 86.99% (95% confidence interval CI 83.54%; 90.44%). The prevalence of self-reported oral side effects was 89.70% (95% CI 86.59; 92.82). The most common oral side effects were xerostomia (73.4%), dysgeusia (61.8%), and dry lips (54.2%). More oral alterations were found in patients with worse periodontal risk (p < 0.001).

Conclusions

The prevalence of oral side effects (professional or self-reported) is higher than 85% in patients undergoing chemotherapy. This prevalence increases as the risk of developing periodontal disease does.

Keywords

Chemotherapy Oral side effects Xerostomia Dysgeusia Periodontal risk 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

“All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”

Informed consent

Informed consent was signed by all the participants in the study.

References

  1. 1.
    Ruiz-Esquide G, Nervi B, Vargas A, Maíz A (2011) Treatment and prevention of cancer treatment related oral mucositis. Rev Med Chil 139(3):373–381.  https://doi.org/10.4067/s0034-98872011000300015 CrossRefPubMedGoogle Scholar
  2. 2.
    Wong HM (2014) Oral complications and management strategies for patients undergoing cancer therapy. Sci World J 2014.  https://doi.org/10.1155/2014/581795
  3. 3.
    Watters A, Epstein J, Agulnik M (2011) Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 47(6):441–448.  https://doi.org/10.1016/j.oraloncology.2011.03.028 CrossRefPubMedGoogle Scholar
  4. 4.
    López BC, Esteve CG, Pérez MGS (2011) Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent 3(1):31–42.  https://doi.org/10.4317/jced.3.e31 CrossRefGoogle Scholar
  5. 5.
    Hsu H-C, Tsai S-Y, Wu S-L, Jeang S-R, Ho M-Y, Liou W-S, Chiang A-J, Chang T-H (2017) Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer. Support Care Cancer 25(11):3457–3464.  https://doi.org/10.1007/s00520-017-3768-7 CrossRefPubMedGoogle Scholar
  6. 6.
    López BC (2014) Oral toxicity produced by chemotherapy: a systematic review. J Clin Exp Dent 6(1):81–90.  https://doi.org/10.4317/jced.51337 CrossRefGoogle Scholar
  7. 7.
    Sonis S, Kunz A (1988) Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol 65(1):19–22.  https://doi.org/10.1016/0030-4220(88)90184-3 CrossRefPubMedGoogle Scholar
  8. 8.
    Sweeney M, Bagg J, Baxter W, Aitchison T (1998) Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol 34(2):123–126.  https://doi.org/10.1016/s1368-8375(97)00076-6 CrossRefPubMedGoogle Scholar
  9. 9.
    Fayle SA, Curzon ME (1991) Oral complications in pediatric oncology patients. Pediatr Dent 13(5):289–295PubMedGoogle Scholar
  10. 10.
    Cheng KKF (2007) Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. J Clin Nurs 16(11):2114–2121.  https://doi.org/10.1111/j.1365-2702.2006.01618.x CrossRefPubMedGoogle Scholar
  11. 11.
    Dodd M, Facione N, Dibble S, MacPhail L (1996) Comparison of methods to determine the prevalence and nature of oral mucositis. Cancer Pract 4(6):312–318PubMedGoogle Scholar
  12. 12.
    Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, Popplewell L, Maghami E (2012) Oral complications of cancer and cancer therapy. CA Cancer J Clin 62(6):400–422.  https://doi.org/10.3322/caac.21157 CrossRefPubMedGoogle Scholar
  13. 13.
    Sonis ST, Lieberman A, Sonis AL (1978) Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 97(3):468–472.  https://doi.org/10.14219/jada.archive.1978.0304 CrossRefPubMedGoogle Scholar
  14. 14.
    Andersson P, Persson L, Hallberg IR, Renvert S (1999) Testing an oral assessment guide during chemotherapy treatment in a Swedish care setting: a pilot study. J Clin Nurs 8(2):150–158.  https://doi.org/10.1046/j.1365-2702.1999.00237.x CrossRefPubMedGoogle Scholar
  15. 15.
    Scully C, Epstein JB (1996) Oral health care for the cancer patient. Eur J Cancer B Oral Oncol 32(5):281–292.  https://doi.org/10.1016/0964-1955(96)00037-1 CrossRefGoogle Scholar
  16. 16.
    Chan CW, Chang AM, Molassiotis A, Lee IY, Lee GC (2003) Oral complications in Chinese cancer patients undergoing chemotherapy. Support Care Cancer 11(1):48–55.  https://doi.org/10.1007/s00520-002-0413-9 CrossRefPubMedGoogle Scholar
  17. 17.
    Konwinska MD, Mehr K, Owecka M, Kulczyk T (2014) Oral health status in patients undergoing chemotherapy for lung cancer. Open J Dent Oral Med 2(1):17–21.  https://doi.org/10.13189/ojdom.2014.020104 CrossRefGoogle Scholar
  18. 18.
    Villafuerte KRV, Martinez CJH, Dantas FT, Carrara HHA, dos Reis FJC, Palioto DB (2018) The impact of chemotherapeutic treatment on the oral microbiota of cancer patients: a systematic review. Oral Surg Oral Med Oral Pathol 125:552–566CrossRefGoogle Scholar
  19. 19.
    Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461.  https://doi.org/10.1002/cncr.28592 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Eilers J, Berger AM, Petersen M (1987) Development, testing, and application of the oral assessment guide. Oncol Nurs Forum 15(3):325–330Google Scholar
  21. 21.
    Serrano JHD (2011) Evaluación de un cuestionario para la asignación del riesgo individual del individuo en el desarrollo de las enfermedades periodontales. Periodoncia y Osteointegración 21(2):133–142Google Scholar
  22. 22.
    Gomes AOF, Junior AS, Noce CW, Ferreira M, Maiolino A, Torres SR (2018) The frequency of oral conditions detected in hematology inpatients. Hematol Transfus Cell Ther 40:240–244.  https://doi.org/10.1016/j.htct.2018.02.006 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Jobbins J, Bagg J, Finlay IG, Addy M, Newcombe R (1992) Oral and dental disease in terminally ill cancer patients. BMJ 304(6842):1612.  https://doi.org/10.1136/bmj.304.6842.1612 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN, Dutilh J, Fulton JS, Jankovic L, Lopes NN (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18(8):1039–1060.  https://doi.org/10.1007/s00520-010-0827-8 CrossRefPubMedGoogle Scholar
  25. 25.
    Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Fusco F, Caruselli A, Cartoni C, Massimo P, Masedu F (2015) Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Support Care Cancer 23(11):3249–3255.  https://doi.org/10.1007/s00520-015-2720-y CrossRefPubMedGoogle Scholar
  26. 26.
    Ponticelli E, Clari M, Frigerio S, De Clemente A, Bergese I, Scavino E, Bernardini A, Sacerdote C (2017) Dysgeusia and health-related quality of life of cancer patients receiving chemotherapy: a cross-sectional study. Eur J Cancer Care 26 (2). doi: https://doi.org/10.1111/ecc.12633
  27. 27.
    Bernhardson B-M, Tishelman C, Rutqvist LE (2008) Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 16(3):275–283.  https://doi.org/10.1007/s00520-007-0319-7 CrossRefPubMedGoogle Scholar
  28. 28.
    Lockhart PB, Sonis ST (1981) Alterations in the oral mucosa caused by chemotherapeutic agents. J Dermatol Surg Oncol 7(12):1019–1025.  https://doi.org/10.1111/j.1524-4725.1981.tb00208.x CrossRefPubMedGoogle Scholar
  29. 29.
    Taichman LS, Van Poznak CH, Inglehart MR (2018) Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments. Spec Care Dentist 38(1):36–45.  https://doi.org/10.1111/scd.12266 CrossRefPubMedGoogle Scholar
  30. 30.
    Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100(S9):1995–2025.  https://doi.org/10.1002/cncr.20162 CrossRefPubMedGoogle Scholar
  31. 31.
    Fitzpatrick SG, Katz J (2010) The association between periodontal disease and cancer: a review of the literature. J Dent 38(2):83–95.  https://doi.org/10.1016/j.jdent.2009.10.007 CrossRefPubMedGoogle Scholar
  32. 32.
    Overholser C, Peterson DE, Williams LT, Schimpff SC (1982) Periodontal infection in patients with acute nonlymphocytic leukemia: prevalence of acute exacerbations. Arch Intern Med 142(3):551–554.  https://doi.org/10.1001/archinte.1982.00340160131025 CrossRefPubMedGoogle Scholar
  33. 33.
    Djuric M, Cakic S, Hadzi-Mihailovic M, Petrovic D, Jankovic L (2010) Oral status in patients receiving 5-fluorouracil for colorectal cancer. J BUON 15(3):475–479PubMedGoogle Scholar
  34. 34.
    Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brunner N, Nauntofte B (2008) Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106(2):217–226.  https://doi.org/10.1016/j.tripleo.2008.04.003 CrossRefPubMedGoogle Scholar
  35. 35.
    Mazzeo MA, Linares JA, Campos ML, Busamia BE, Dubersarsky C, Lavarda M, Jarchum G, Finkelberg AB (2009) Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment. Med Oral Patol Oral Cir Bucal 14(3):E108–E113PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • B. García-Chías
    • 1
  • E. Figuero
    • 1
    • 2
    Email author
  • B. Castelo-Fernández
    • 3
  • J. L. Cebrián-Carretero
    • 4
  • R. Cerero-Lapiedra
    • 1
  1. 1.Department of Dental Clinical Specialties, Faculty of DentistryUniversidad Complutense de MadridMadridSpain
  2. 2.ETEP (Etiology and Therapy of Periodontal Diseases) Research Group. Faculty of DentistryUniversidad Complutense de MadridMadridSpain
  3. 3.Department of Medical Oncology, University Hospital La PazAutonoma University MadridMadridSpain
  4. 4.Department of Oral and Maxillofacial Surgery, La Paz University HospitalAutonoma University MadridMadridSpain

Personalised recommendations